LQDA

Liquidia Corp

Pharmaceutical Preparations · SIC 2834CIK 1819576Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$158.0M

Net Income FY2025

$(69.0M)

EPS (Basic, as reported)

$-0.80

Net Margin FY2025

-43.5%

ROE FY2025

-154.0%

Total Equity

$45.0M

Shares Out

90M

Business description

Liquidia Corp — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 8 → 158 +64.4% CAGR

Fiscal yearFY2019FY2020⚑FY2021FY2022FY2023FY2024FY2025

Revenue8113161714158

Cost of revenue—0(3)(3)(3)(6)—

Research & development(40)(32)(21)(19)(43)(48)(39)

Selling, general & administrative————(45)(82)(157)

General & administrative(14)(27)(23)(32)(45)(82)—

Total operating expenses(55)(60)(47)(55)(91)(135)(210)

Operating income(47)(59)(34)(39)(73)(121)(51)

Interest expense(1)(1)(1)(2)(6)(12)(24)

Interest & investment income1001387

Other income (expense), net(1)(1)(1)(2)(5)(9)(18)

Income tax expense0000000

Net income(48)(60)(35)(41)(79)(130)(69)

EPS — basic—($1.76)($0.70)($0.67)($1.21)($1.66)($0.80)

EPS — diluted($2.57)($1.76)($0.70)($0.67)($1.21)($1.66)($0.80)

Shares outstanding — basic (M)—345061657986

Shares outstanding — diluted (M)18345061657986

⚑ Weighted-average shares changed ×1.47 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.